Astex Therapeutics Limited

Novartis Ag

Otsuka Pharmaceutical Company, Limited

Taiho Pharmaceutical Company Limited

Cancer Research Technology Limited

The Institute of Cancer Research: Royal Cancer Hospital

Concateno UK Limited

Invitron Limited

Concateno Plc

Andrew James Woodhead

Maria Grazia Carr

Alison Jo-Anne Woolford

Michael Alistair O'Brien

Martyn Frederickson

Miles Stuart Congreve

Valerio Berdini

Gianni Chessari

Christopher William Murray

Paul Graham Wyatt

Adrian Liam Gill

Gary Trewartha

Theresa Rachel Early

Eva Figueroa Navarro

Robert Downham

Theresa Rachel Phillips

Brian John Williams

Steven Howard

Neil Thomas Thompson

Christopher Charles Frederick Hamlett

Steven Douglas Hiscock

John Francis Lyons

Mladen Vinkovic

Michael Alistair O'brien

Patrick René Angibaud

Christopher Norbert Johnson

Andrew Madin

Michael Luzzio

Eddy Jean Edgard Freyne

Gordon Saxty

Ildiko Maria Buck

Bharat Lagu

Charlotte Mary Griffiths-Jones

Lawrence Blas Perez

Gilbert Besong

Fan Yang

Christine Hiu-Tung Chen

Christopher Thomas Brain

David Norton

James Edward Harvey Day

Steven John Woodhead

James Stuart Woodhead

Young Shin Cho

Yaping Wang

Jeffrey David St Denis

John William Giraldes

Rhian Sara Holvey

Emma Vickerstaffe

Sunkyu Kim

Gordon Thomas Jowett

Claudio Dagostin

Marc O'Reilly

Tom Cornelis Hortense Govaerts

Hendrika Maria Gerarda Willems

Nicholas John Palmer

Yipin Lu

Alessia Millemaggi

Hideto Fujiwara

Paul Mortenson

John Walter Liebeschuetz

Susanne Maria Saalau-Bethell

Rajdeep Kaur Benning

Lynsey Helen Fazal

David Geoffrey Twigg

Charlotte Mary Griffiths-jones

Michael Joseph Luzzio

Alison Jo-Ann Woolford

Paul Neil Mortenson

John Grialdes

Valerio 436 Cambridge Science Park Berdini

Maria Grazia 436 Cambridge Science Park Carr

Paul Graham 436 Cambridge Science Park Wyatt

Theresa Rachel 436 Cambridge Science Park Early

AdrianL 436 Cambridge Science Park Gill

Gary 436 Cambridge Science Park Trewartha

The invention provides new pyrazine derivatives of formula (I): or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein. The invention also provides pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Pharmaceutical compounds

The invention concerns a cartridge for performing sample analysis in a portable point of care test device (POCT); a point of care assay device, comprising said cartridge and a reader for accommodating said cartridge, for detecting and/or quantifying an analyte in a sample; and a kit of parts comprising the said components of said point of care assay device.

Device platform for point of care testing

The invention provides compounds of the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein Ris hydroxy or hydrogen; Ris hydroxy; methoxy or hydrogen; provided that at least one of Rand Ris hydroxy; Ris selected from hydrogen; halogen; cyano; optionally substituted Chydrocarbyl and optionally substituted Chydrocarbyloxy; Ris selected from hydrogen; a group &#x2014;(O)&#x2014;Rwhere n is 0 or 1 and Ris an optionally substituted acyclic Chydrocarbyl group or a monocyclic carbocyclic or heterocyclic group having 3 to 7 ring members; halogen; cyano; hydroxy; amino; and optionally substituted mono- or di-Chydrocarbyl-amino; or Rand Rtogether form a monocyclic carbocyclic or heterocyclic ring of 5 to 7 ring members; and NRRforms an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 ring members are heteroatoms selected from oxygen, nitrogen and sulphur. The compounds have activity as Hsp90 inhibitors.

Hydroxybenzamide derivatives and their use as inhibitors of HSP90

The invention provides an acid addition salt of a compound of the formula (1). Also provided by the invention are processes for preparing the compound of formula (1) and alkyl analogs thereof, novel intermediates for use in the process and methods for preparing the intermediates. The invention also provides new medical uses of compounds of the formula (1) and its ethyl analog.

Hydrobenzamide derivatives as inhibitors of Hsp90

According to a first aspect of the present invention there is provided an oral fluid collection device. The oral fluid collection device comprises a handle, a swab holder, and a swab. The swab is in the form of a hollow tube of absorbent material coaxially located about the swab holder, such that the swab is supported by the swab holder along the entire length of the swab.

Oral fluid collection device

The invention provides compounds that are useful in the treatment of hepatitis C virus (HCV) infections. The compounds have the formula (1): or a salt, N-oxide, tautomer or stereoisomer thereof, wherein A is CH or N; E is CH or N;

The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3.  In formula (0):

3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators

The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of diseases, e.g. cancer.

Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases

The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof, and combinations thereof with other anti-cancer agents, for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3. 

The invention provides a compound for use in medicine, the compound being a compound of the formula (VI) or a salt, solvate, tautomer or N-oxide thereof: wherein the bicyclic group: is selected from the structures C1, C5 and C6: wherein n is 0, 1, 2 or 3; Ris hydrogen, hydroxy, or O&#x2014;R; Ris hydroxy, methoxy or O&#x2014;R; provided that at least one of Rand Ris O&#x2014;R; Ris L-R; SOH; a glucuronide residue; a mono-, di- or tripeptide residue; or Lis a bond, C&#x2550;O, (C&#x2550;O)O, (C&#x2550;O)NRor S(O)NR; x is 1 or 2; Ris hydrogen or a an optionally substituted Chydrocarbyl group containing 0, 1 or 2 carbocyclic rings and 0, 1, 2, 3, 4, 5 or 6 carbon-carbon multiple bonds, provided that Ris not hydrogen when Lis a bond, C&#x2550;O or (C&#x2550;O)O; and provided also that O&#x2014;Rdoes not contain an O&#x2014;O moiety; and excluding compounds wherein Ris hydroxy and Ris methoxy; Rand Rare the same or different and each is a group R; and R, R, Rand Rare defined in the claims. The compounds of formula (VI) are pro-drugs of parent compounds wherein Rand/or Rare hydroxy, wherein the parent compounds have Hsp90 inhibiting activity.

The invention provides an acid addition salt of a compound of the formula (1) Also provided by the invention are processes for preparing the compound of formula (1) and alkyl analogues thereof, novel intermediates for use in the process and methods for preparing the intermediates. The invention also provides new medical uses of compounds of the formula (1) and its ethyl analogue.

The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof;wherein Q is CH or N; X is N, N&#x2014;Oor CR; Y is N, N&#x2014;Oor CR; Rand Rare independently selected from hydrogen and various substituents as defined in the claims; or Rand Rtogether with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; Ris selected from hydrogen and various substituents; and Ris selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of inter alia proliferative diseases such as cancers.

Imidazole derivatives and their use as modulators of cyclin dependent kinases

The invention provides a combination comprising an Hsp90 inhibitor compound of the formula (VII): or tautomer or salt thereof and one or more therapeutic agents selected from topoisomerase I inhibitors; antimetabolites; tubulin targeting agents; DNA binder and topoisomerase II inhibitors; alkylating agents; monoclonal antibodies; anti-hormones; signal transduction inhibitors; proteasome inhibitors; DNA methyl transferases; cytokines; retinoids and HDAC or HAT modulators.

Therapeutic combinations of hydroxybenzamide derivatives as inhibitors of HSP90

This invention provides methods for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate cancer, lung cancer, gastrointestinal stromal tumor, breast cancer and melanoma, which comprise administering to the mammal a compound, salt, hydrate, tautomer or N-oxide according to formula (I): and in particular, those of subgenus VIIa  These compounds inhibit or modulate the activity of the heat shock protein Hsp90.

Dihydroxyphenyl isoindolylmethanones

Growing community of inventors

Cambridge, United Kingdom

Andrew James Woodhead